Ultrashort Flare GnRH Agonist Combined With Flexible Multidose GnRH Antagonist Versus Flexible Multidose GnRH Antagonist for Good-prognosis IVF Patients
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Infertility
- Sponsor
- Sheba Medical Center
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Ongoing pregnancy rates
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the appropriate controlled ovarian hyperstimulation (COH) protocol in good prognosis patients undergoing IVF treatment. The stimulation characteristics of cycles which include ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist will be compared to the flexible multidose GnRH antagonist protocol.
The investigators hypothesized that combining the stimulatory effect of GnRH agonists and immediate suppression of the GnRH antagonist in a unique protocol may be a valuable new COH strategy for IVF patients, resulting in improved ART outcome.
Detailed Description
The ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist protocol during COH cycle resulted in a significantly higher clinical pregnancy rate in patients with poor embryo quality, with repeated IVF failures and in poor responders. This protocol combines the effect of the microdose flare on endogenous follicle stimulating hormone (FSH) release with the benefit of an immediate luteinizing hormone suppression of the GnRH antagonist. The basic hypothesis of this approach can also benefit IVF patients with good prognosis without compromising the ability to use gonadotrophin-releasing hormone (GnRH) agonist to effectively trigger ovulation, while completely eliminating any threat of clinically significant ovarian hyperstimulation syndrome (OHSS). The purpose of the study is to compare cycles consisting of ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist with those using the flexible multidose GnRH antagonist protocol 1. To compare the IVF outcome variables and ongoing pregnancy rates.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Up to three previous IVF attempts
Exclusion Criteria
- •Patients with poor or no response in previous COH for IVF cycles
- •Abnormal ovarian reserve test i.e. anti-mullerian hormone (AMH), Antral follicle test
- •Risk factor for Diminished Ovarian Reserve
Outcomes
Primary Outcomes
Ongoing pregnancy rates
Time Frame: 2 years
Secondary Outcomes
- Total gonadotropin use(2 Years)
- Biochemical pregnancy(2 Years)
- Clinical pregnancy(2 Years)
- Multiple pregnancy rate(2 Years)
- Miscarriage rate(2 Years)
- Fertilization rate(2 Years)
- Number of oocytes(2 years)
- OHSS rates(2 Years)
- Embryo quality(2 Years)